GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brii Biosciences Ltd (HKSE:02137) » Definitions » Cash Flow from Investing

Brii Biosciences (HKSE:02137) Cash Flow from Investing : HK$696.47 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Brii Biosciences Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the six months ended in Jun. 2024, Brii Biosciences spent HK$0.82 Mil on purchasing property, plant, equipment. It gained HK$0.00 Mil from selling property, plant, and equipment. It spent HK$0.00 Mil on purchasing business. It gained HK$0.00 Mil from selling business. It spent HK$13.24 Mil on purchasing investments. It gained HK$500.08 Mil from selling investments. It paid HK$0.00Mil for net Intangibles purchase and sale. And it paid HK$61.95 Mil for other investing activities. In all, Brii Biosciences gained HK$424.06 Mil on investment activities in financial market and operating subsidiaries for the six months ended in Jun. 2024.


Brii Biosciences Cash Flow from Investing Historical Data

The historical data trend for Brii Biosciences's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brii Biosciences Cash Flow from Investing Chart

Brii Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
-103.24 -51.74 -582.55 -1,600.44 -114.14

Brii Biosciences Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only 299.59 -1,885.85 -386.55 272.42 424.06

Brii Biosciences Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Brii Biosciences's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Brii Biosciences's Cash Flow from Investing for the quarter that ended in Jun. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$696.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Brii Biosciences  (HKSE:02137) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Brii Biosciences's purchase of property, plant, equipment for the six months ended in Jun. 2024 was HK$-0.82 Mil. It means Brii Biosciences spent HK$0.82 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Brii Biosciences's sale of property, plant, equipment for the six months ended in Jun. 2024 was HK$0.00 Mil. It means Brii Biosciences gained HK$0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Brii Biosciences's purchase of business for the six months ended in Jun. 2024 was HK$0.00 Mil. It means Brii Biosciences spent HK$0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Brii Biosciences's sale of business for the six months ended in Jun. 2024 was HK$0.00 Mil. It means Brii Biosciences gained HK$0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Brii Biosciences's purchase of investment for the six months ended in Jun. 2024 was HK$-13.24 Mil. It means Brii Biosciences spent {stock_data.stock.currency_symbol}}13.24 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Brii Biosciences's sale of investment for the six months ended in Jun. 2024 was HK$500.08 Mil. It means Brii Biosciences gained HK$500.08 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Brii Biosciences's net Intangibles purchase and sale for the six months ended in Jun. 2024 was HK$0.00 Mil. It means Brii Biosciences paid HK$0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Brii Biosciences's cash from discontinued investing activities for the six months ended in Jun. 2024 was 0.00 Mil. It means Brii Biosciences paid HK$0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Brii Biosciences's cash from other investing activities for the six months ended in Jun. 2024 was HK$-61.95 Mil. It means Brii Biosciences paid HK$61.95 Mil for other investing activities.


Brii Biosciences Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Brii Biosciences's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Brii Biosciences Business Description

Traded in Other Exchanges
Address
No. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed to developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as CNS diseases, which have public health burdens in China and worldwide. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
Executives
Hong Zhi 2101 Beneficial owner
Xyxy Holdings Ltd. 2201 Interest of corporation controlled by you
Booming Passion Limited 2101 Beneficial owner
Boyu Capital Fund Iii, L.p. 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, L.p. 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, Ltd 2201 Interest of corporation controlled by you
Tong Xiaomeng 2201 Interest of corporation controlled by you
Boyu Group, Llc 2201 Interest of corporation controlled by you
Boyu Capital Group Holdings Ltd 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Invesco Advisers, Inc. 2102 Investment manager
Ma Yun 2201 Interest of corporation controlled by you
Yunfeng Investment Iii, Ltd. 2201 Interest of corporation controlled by you
Yunfeng Fund Iii, L.p. 2201 Interest of corporation controlled by you
Yf Bright Insight Limited 2101 Beneficial owner

Brii Biosciences Headlines

No Headlines